- Home
- CYBN vs ALDX Comparison
CYBN vs ALDX Comparison
Compare CYBN & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- ALDX
- Stock Information
- Founded
- CYBN 2019
- ALDX 2004
- Country
- CYBN Canada
- ALDX United States
- Employees
- CYBN N/A
- ALDX N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- CYBN Health Care
- ALDX Health Care
- Exchange
- CYBN Nasdaq
- ALDX Nasdaq
- Market Cap
- CYBN 174.9M
- ALDX 160.8M
- IPO Year
- CYBN N/A
- ALDX 2014
- Fundamental
- Price
- CYBN $7.71
- ALDX $3.05
- Analyst Decision
- CYBN Strong Buy
- ALDX Strong Buy
- Analyst Count
- CYBN 4
- ALDX 2
- Target Price
- CYBN $86.00
- ALDX $9.50
- AVG Volume (30 Days)
- CYBN 310.7K
- ALDX 769.8K
- Earning Date
- CYBN 08-07-2025
- ALDX 07-31-2025
- Dividend Yield
- CYBN N/A
- ALDX N/A
- EPS Growth
- CYBN N/A
- ALDX N/A
- EPS
- CYBN N/A
- ALDX N/A
- Revenue
- CYBN N/A
- ALDX N/A
- Revenue This Year
- CYBN N/A
- ALDX N/A
- Revenue Next Year
- CYBN N/A
- ALDX N/A
- P/E Ratio
- CYBN N/A
- ALDX N/A
- Revenue Growth
- CYBN N/A
- ALDX N/A
- 52 Week Low
- CYBN $4.81
- ALDX $1.14
- 52 Week High
- CYBN $13.88
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- CYBN 50.59
- ALDX 61.89
- Support Level
- CYBN $7.50
- ALDX $2.60
- Resistance Level
- CYBN $9.20
- ALDX $3.24
- Average True Range (ATR)
- CYBN 0.56
- ALDX 0.22
- MACD
- CYBN -0.12
- ALDX 0.09
- Stochastic Oscillator
- CYBN 27.06
- ALDX 80.93
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.